- Home
- SSL vs INDV Comparison
SSL vs INDV Comparison
Compare SSL & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SSL | INDV |
|---|---|---|
| Founded | 1950 | N/A |
| Country | South Africa | United States |
| Employees | 27411 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 4.7B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | SSL | INDV |
|---|---|---|
| Price | $13.51 | $36.95 |
| Analyst Decision | Sell | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.5M | ★ 2.0M |
| Earning Date | 04-24-2026 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8100.00 |
| EPS | N/A | ★ 0.69 |
| Revenue | N/A | ★ $1,239,000,000.00 |
| Revenue This Year | $3.79 | N/A |
| Revenue Next Year | $4.39 | N/A |
| P/E Ratio | ★ $13.51 | $54.88 |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $3.90 | $11.07 |
| 52 Week High | $14.37 | $41.00 |
Technical Indicators
Market Signals| Indicator | SSL | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 56.03 | 54.73 |
| Support Level | $11.82 | $34.91 |
| Resistance Level | $13.68 | $37.83 |
| Average True Range (ATR) | 0.33 | 1.48 |
| MACD | -0.09 | -0.16 |
| Stochastic Oscillator | 57.66 | 42.11 |
Price Performance
Historical ComparisonAbout SSL Sasol Ltd.
Sasol Ltd operates as a vertically integrated chemicals and energy company through its two main businesses: the Southern Africa Energy & Chemicals business and the International Chemical business. It generates maximum revenue from the Southern Africa Energy & Chemicals business, which operates integrated value chains with feedstock sourced from the Mining and Gas operating segments. Geographically, the company generates the majority of its revenue from South Africa.
About INDV Indivior PLC
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).